Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 3, 2009, Pages 277-283

  Liu, Hai Bo ^a   Kong, Chui Ze ^a   Zeng, Yu ^a,b   Liu, Xian Kui ^a   Bi, Jian Bin ^a   Jiang, Yuan Jun ^a   Han, Sheng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bladder cancer; IAP; Livin; Relapse; Transfection

Indexed keywords

ACRIDINE ORANGE; CASPASE 3; COMPLEMENTARY DNA; LIVIN;

APOPTOSIS; ARTICLE; ASSAY; BLADDER CANCER; CANCER CELL; CANCER RELAPSE; CANCER THERAPY; CELL CLONE; CELL PROLIFERATION; COLONY FORMATION; ENZYME ACTIVITY; FLOW CYTOMETRY; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG THERAPY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 65349188074     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.03.015     Document Type: Article

References (45)

1. Jaattela M. Escaping cell death: Survival proteins in cancer. Exp Cell Res 248 (1999) 30-43
2. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11 (1999) 68-75
3. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
4. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 17 (1999) 2941-2953
5. LaCasse E.C., Baird S., Korneluk R.G., et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
6. Deveraux Q.L., Roy N., Stennicke H.R., et al. IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17 (1998) 2215-2223
7. Hengartner M.O. Genetic control of programmed cell death and aging in the nematode Caenorhabditis elegans. Exp Gerontol 32 (1997) 363-374
8. Cohen G.M. Caspases: The executioners of apoptosis. Biochem J 326 (1997) 1-16
9. Thornberry N.A. The caspase family of cysteine proteases. Br Med Bull 53 (1997) 478-490
10. Hengartner M.O. Death cycle and Swiss army knives. Nature 391 (1998) 441-442
11. Crook N.E., Clem R.J., and Miller L.K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 67 (1993) 2168-2174
12. Rothe M., Pan M.G., Henzel W.J., et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995) 1243-1252
13. Duckett C.S., Nava V.E., Gedrich R.W., et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J 15 (1996) 2685-2694
14. Liston P., Roy N., Tamai K., et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379 (1996) 349-353
15. Ambrosini G., Adida C., and Altieri D.C. A novel antiapoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
16. Salvesen G.S., and Duckett C.S. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 3 (2002) 401-410
17. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 997;16:6914-25.
18. Chu Z.L., McKinsey T.A., Liu L., et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci USA 94 (1997) 10057-10062
19. You M., Ku P.T., Hrdlickova R., et al. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol 17 (1997) 7328-7341
20. Takahashi R., Deveraux Q., Tamm I., et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 273 (1998) 7787-7790
21. Clem R.J., and Miller L.K. Control of programmed cell death by the baculovirus genes p35 and IAP. Mol Cell Biol 14 (1994) 5212-5222
22. Lin J.H., Deng G., Huang Q., et al. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun 279 (2000) 820-831
23. Kasof G.M., and Gomes B.C. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276 (2001) 3238-3246
24. Vucic D., Stennicke H.R., Pisabarro M.T., et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10 (2000) 1359-1366
25. Ashhab Y., Alian A., Polliack A., et al. Two splicing variants of anew inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 495 (2001) 56-60
26. Yagihashi A., Asanuma K., Tsuji N., et al. Detection of anti-Livin antibody in gastrointestinal cancer patients. Clin Chem 49 (2003) 1206-1208
27. Gazzaniga P., Gradilone A., Giuliani L., et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14 (2003) 85-90
28. Kim D.K., Alvarado C.S., Abramowsky C.R., et al. Expression of inhibitor-of-apoptosis protein (IAP) Livin by neuroblastoma cells: Correlation with prognostic factors and outcome. Pediatr Dev Pathol 8 (2005) 621-629
29. Eller M.S., Ostrom K., and Gilchrest B.A. DNA damage enhances melanogenesis. Proc Natl Acad Sci USA 93 (1996) 1087-1092
30. Loo D.T., and Rillema J.R. Measurement of cell death. Methods Cell Biol 57 (1998) 251-264
31. Youn B.S., Kim Y.J., Mantel C., et al. Blocking of c-FLIP(L) independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood 98 (2001) 925-933
32. Jinquan T., Jacobi H.H., Jing C., et al. CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells. J Immunol 171 (2003) 1722-1731
33. Ansell S.M., Arendt B.K., Grote D.M., et al. Inhibition of Survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18 (2004) 616-623
34. Pennati M., Binda M., Colella G., et al. Ribozyme-mediated inhibition of Survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23 (2004) 386-394
35. Liu T., Brouha B., and Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 23 (2004) 39-48
36. Andersen M.H., Reker S., Becker J.C., et al. The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses. J Invest Dermatol 122 (2004) 392-399
37. Bortner C.D., and Cidlowski J.A. Cellular mechanisms for the repression of apoptosis. Annu Rev Pharmacol Toxicol 42 (2002) 259-281
38. Rothe M., Pan M.G., Henzel W.J., et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995) 1243-1252
39. Deveraux Q.L., and Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev 13 (1999) 239-252
40. Vucic D., Deshayes K., Ackerly H., et al. SMAC negatively regulates the antiapoptotic activity of melanoma inhibitor of apoptosis (MLIAP). J Biol Chem 277 (2002) 12275-12279
41. Vucic D., Franklin M.C., Wallweber H.J., et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for SMAC-dependent antiapoptotic activity of ML-IAP. Biochem J 385 (2005) 11-20
42. + T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of Livin activation. Cancer Res 64 (2004) 7579-7587
43. Nachmias B., Ashhab Y., Bucholtz V., et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 63 (2003) 6340-6349
44. Hariu H., Hirohashi Y., Torigoe T., et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 11 (2005) 1000-1009
45. Hara I., Miyake H., Takechi Y., et al. Clinical outcome of conservative therapy for stage T1, grade3 transitional cell carcinoma of the bladder. Int J Urol 10 (2003) 19-24